Physiological Indirect Effect Modeling of the Antilipolytic Effects of Adenosine A1-Receptor Agonists
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The relationship between blood concentrations of the adenosine A 1 -receptor agonist N6 -(p-sulfophenyI)adenosine (SPA) and its effect on both plasma nonesterified fatty acid (NEFA) and glycerol release was described on the basis of an integrated pharmacokinetic–pharmacodynamic model. An indirect response model rather than a hypothetical “link” model was used to account for the delayed response. For that purpose an empirical solution to the differential equation describing the physiological indirect response model is presented. The model-estimated rate constant for the output of the glycerol response was compared to the elimination rate constant after exogenous administration of glycerol. In a crossover designed study, chronically cannulated male Wistar rats were subjected to either SPA administration (120 μg/kg for 15 min) for measurement of the effects on glycerol, or glycerol administration for determination of glycerol pharmacokinetics. Glycerol pharmacokinetics was determined in the presence of a stable level of SPA (171±6ng/ml) to suppress endogenous glycerol levels completely. The indirect response model adequately described the relationship between SPA concentrations and plasma glycerol levels. The PD parameter estimates for EC 50 , Emax , and Hill factor were 23±2 ng/ml, 74±3% (change from baseline), and 3.3±0.5, respectively. These values were not different from those obtained when analyzing the data on basis of the differential equation directly. Furthermore the EC50 values for the reduction in glycerol or NEFA levels were identical (23±2 and 21±3 ng/ml, respectively) indicating that both PD end points reflect the same physiological process. The concentration–time profile after administration of glycerol could be described best on the basis of a biexponential function. The value for kout in the PK/PD model (0.19±0.03 min −1 ) corresponded very well to the terminal elimination rate constant determined after iv administration of glycerol (0.25±0.03 min −1 ). In conclusion, the antilipolytic effects of adenosine A 1 -receptor agonists can be described by the indirect suppression model. The rate constant describing the delay between concentration and glycerol effect was shown to be a true reflection of the removal of glycerol.
- M. Williams. Purinergic drugs: opportunities in the 1990s. Drug Dev. Res. 28:438–444 (1993).
- J. E. Foley. Rationale for activation of adenosine A1 receptors in adipocytes in the treatment of non-insulin dependent diabetes mellitus. Drug. Dev. Res. 32:126 (1994).
- K. A. Jacobson, P. J. M. van Galen, and M. Williams. Adenosine receptors: Pharmacology, structure-activity relationships, and therapeutic potential. J. Med. Chem. 35:407–422 (1992).
- R. A. A. Mathôt, E. A. van Schaick, M. W. E. Langemeijer, W. Soudijn, D. D. Breimer, A. P. IJzerman, and M. Danhof. Pharmacokinetic-pharmacodynamic relationship of the cardiovascular effects of adenosine A1 receptor agonist N 6-cyclopentyladenosine in the rat. J. Pharmacol. Exp. Ther. 268:616–624 (1994).
- R. A. A. Mathôt, E. M. van der Wenden, W. Soudijn, A. P. IJzerman, and M. Danhof. Deoxyribose analogues of N 6-cyclopentyladenosine (CPA): Partial agonists at the adenosine A1 receptor in vivo. Br. J. Pharmacol. 116:1957–1964 (1995).
- E. A. van Schaick, H. J. M. M. de Greef, M. W. E. Langemeijer, M. J. Sheehan, A. P. IJzerman, and M. Danhof. Pharmacokinetic-pharmacodynamic modelling of the anti-lipolytic and anti-ketotic effects of the adenosine A1-receptor agonist N 6-(p-sulfophenyl) adenosine in rats. Br. J. Pharmacol. 122:525–533, 1997.
- P. J. Randle, C. N. Hales, P. B. Garland, and E. A. Newsholme. The glucose fatty acid cycle: its role in insulin sensitivity and the metabolic disturbances in diabetes mellitus. Lancet 1:785–789 (1969).
- G. M. Reaven and Y-D. I. Chen. Role of abnormal free fatty acid metabolism in the development of non-insulin dependent diabetes mellitus. Am. J. Med. 85:106–112 (1988).
- J. D. McGarry. What if Minkowski had been ageusic? An alternative angle on diabetes. Science 258:766–770 (1992).
- C. Londos, R. C. Honner, and G. S. Dhillon. c-AMP dependent protein kinase and lipolysis in rat adipocytes. III. Multiple modes of insulin regulation of lipolysis and regulation of insulin responses by adenylate cyclase. J. Biol. Chem. 260:15139–15145 (1985).
- K. A. Jacobson, O. Nikodijevi, X. Ji, D. A. Berkich, D. Eveleth, R. L. Dean, K. Hiramatsu, N. F. Kassel, P. J. M. van Galen, K. S. Lee, R. T. Bartus, J. W. Daly, K. F. LaNoue, and M. Maillard. Synthesis and biological activity of N 6-(p-sulfophenyl)alkyl and N 6-sulfoalkyl derivatives of adenosine: Water-soluble and peripherally selective adenosine agonists. J. Med. Chem. 35:4143–4149 (1992).
- M. Gibaldi and D. Perrier. Non-compartmental analysis based on statistical moment theory. In Pharmacokinetics, 2nd ed., Marcel Dekker, New York, 1982, pp. 409–424.
- K. Yamoaka, T. Nakagawa, and T. Uno. Application of Aikaike's information criterion (AIC) in the evaluation of linear pharmacokinetics. J. Pharmacokin. Biopharm. 6:165–175 (1978).
- N. L. Dayneka, V. Garg, and J. W. Jusko. Comparison of four basic models of indirect pharmacodynamic responses. J. Pharmacokin. Biopharm. 21:457–478 (1993).
- A. I. Nichols and W. J. Jusko. Receptor-mediated prednisolone pharmacodynamics in rats: verification using a dose-sparing regimen. J. Pharmacokin. Biopharm. 18:189–208 (1990).
- S. K. Yamashita, E. A. Ludwig, E. Middleton, and J. W. Jusko. Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. Clin. Pharmacol. Ther. 49:558–570 (1991).
- A. I. Nichols, R. D'Ambrosio, N. A. Pyszcynski, and J. W. Jusko. Pharmacokinetics and pharmacodynamics of prednisolone in obese rats. J. Pharmacol. Exp. Ther. 250:963–970 (1989).
- J. M. T. van Griensven, J. W. Jusko, H. H. P. J. Lemkes, R. Kroon, C. J. Verhorst, S. T. Chiang, and A. F. Cohen. Tolrestat pharmacokinetic and pharmacodynamic effects on red blood cell sorbitol levels in normal volunteers and in patients with insulin-dependent diabetes. Clin. Pharmacol. Ther. 58: 631–640 (1995).
- U. Schwabe, R. Ebert, and H. C. Erbler. Adenosine release from isolated fat cells and its significance for the effects of hormones on cyclic 3′,5′-AMP levels and lipolysis. Naunyn-Schmeidebergs Arch. Exp. Pathol. Pharmakol. 276:133–148 (1973).
- W. J. Jusko and H. C. Ko. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin. Pharmacol. Ther. 56:406–419 (1994).
- K. N. Frayn, C. M. Williams, and P. Arner. Are increased plasma non-esterified fatty acid concentrations a risk marker for coronary heart disease and other chronic diseases? Clin. Sci. 90:243–253 (1996).
- R. H. Ackermann, K. H. Bässler, and K. Wagner. Glyzerin: Ausnutzung, Umsatzkapazität und biokinetische Daten unter intravenöser Zufuhr bei der Ratte. Infusionstherapie 2:9–15 (1975).
- P. Strong, R. Anderson, J. Coates, F. Ellis, B. Evans, M. F. Gurden, J. Johnstone, I. Kennedy, and D. P. Martin. Suppression of non-esterified fatty acids and triacylglycerol in experimental animals by the adenosine analogue GR79236. Clin. Sci. 84:663–669 (1993).
- C. J. Gardner, D. J. Twissell, J. Coates, and P. Strong. The effects of GR79236 on plasma fatty acid concentrations, heart rate and blood pressure in the conscious rat. Eur. J. Pharmacol. 257:117–121 (1994).
- G. M. Reaven, H. Chang, H. Ho, C. I. Jeng, and B. Hoffman. Lowering of plasma glucose in diabetic rats by antilipolytic agents. Am. J. Physiol. 254:E23–30 (1988).
- M. G. Collis and S. M. O. Hourani. Adenosine receptor subtypes. Trends Pharmacol. Sci. 14:360–366 (1993).
- C. C. Peck, W. H. Barr, L. Z. Benet, J. Collins, R. E. Desjardins, D. E. Furst, J. G. Harter, G. Levy, T. Ludden, J. H. Rodman, L. Sanathan, J. J. Schentag, V. P. Shah, L. B. Sheiner, J. P. Kelly, D. R. Stanski, R. J. Temple, C. T. Viswanathan, J. Weissinger, and A. Yacobi. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Clin. Pharmacol. Ther. 51:465–473 (1992).
- M. Gibaldi and D. Perrier. Method of Laplace transforms. In Pharmacokinetics, 2nd ed., Marcel Dekker, New York, 1975, pp. 267–272.
- Physiological Indirect Effect Modeling of the Antilipolytic Effects of Adenosine A1-Receptor Agonists
Journal of Pharmacokinetics and Biopharmaceutics
Volume 25, Issue 6 , pp 673-694
- Cover Date
- Print ISSN
- Online ISSN
- Kluwer Academic Publishers-Plenum Publishers
- Additional Links
- adenosine A1-receptor
- N 6-(p-sulfophenyl)adenosine
- pharmacokinetic–pharmacodynamic modeling
- indirect response
- conscious rats
- Industry Sectors